Preview

Пульмонология

Расширенный поиск

Основные положения международных клинических рекомендаций по диагностике и лечению хронической обструктивной болезни легких

https://doi.org/10.18093/0869-0189-2005-0-3-108-118

Полный текст:

Об авторах

И. В. Лещенко
ГОУ ВПО Уральская государственная медицинская академия МЗ и СР РФ
Россия
Екатеринбург


Н. А. Эсаулова
ГОУ ВПО Уральская государственная медицинская академия МЗ и СР РФ
Россия
Екатеринбург


Список литературы

1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Bethesda: National Heart, Lung and Blood Institute: April 2001. NIH Publication No. 2701. 1–100.

2. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute: update 2003 (www.goldcopd.com).

3. Чучалин А.Г. (ред.) Хроническая обструктивная болезнь легких. (Федеральная программа.) Практическое руководство для врачей. 2-е изд. М.; 2004.

4. NICE Guideline №12. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Developed by the National Collaborating Centre for Chronic Conditions. Thorax 2004; 59 (suppl. 1): 1–232.

5. Chronic Obstructive Pulmonary Disease. Guideline ATS, ERS 2004. www.thoracic.org/COPD.

6. Сelli B.R., MacNee W., and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS-position paper. Eur. Respir. J. 2004; 23 (6): 932–946.

7. Mannino D.M., Gagnon R.C., Petty T.L., Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 2000; 160: 1683–1989.

8. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance — United States, 1971–2000. Morbid. Mortal. Wkly Rep. 2002; 51: 1–16.

9. Vestbo J., Prescott E., Lange P., and the Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and COPD morbidity. Am. J. Respir. Crit. Care Med. 1996; 153: 1530–1535.

10. Prescott E., Vestbo J. Socioeconomic status and chronic obstructive pulmonary disease. Thorax 1999; 54: 737–741.

11. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.

12. Sullivan S.D., Ramsey S.D., Lee T.A. The economic burden of COPD. Chest 2000; 117: 5S–9S.

13. Mahler D.A., Rosiello R.A., Harver A. et al. Comparison of clinical dyspnea ratings and psychophysical measurements on respiratory sensation in obstructive airway disease. Am. Rew. Respir. Dis. 1987; 135: 1229–1233.

14. O'Donnell D.E., Lam M., Webb K.A. Spirometric correlates of improvement in exercise performance after anthicholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542–549.

15. Belman M.J., Botnick W.C., Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 967–975.

16. Disse B., Speck G., Rominger K. et al. Tiotropium (Spiriva™): Mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64: 457–464.

17. Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.

18. On L.S., Boonyongsunchai P., Webb S. et al. Function of pulmonary neuronal m2 muscarinic receptors in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1320–1325.

19. Profita M., Giorgi R., Sala A. et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients [abstract 264]. Eur. Respir. J. 2004; 24 (suppl. 48): 20s.

20. Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–1748.

21. O'Donnell D.E., Fluge T., Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832–840.

22. Dusser D., Bravo M.1L., Iacono P., on Behalf of the MISTRAL Study Group. Tiotropium reduces COPD exacerbations: the MISTRAL study [abstract 3203]. Eur. Respir. J. 2004; 24 (suppl. 48): 513s.

23. Dusser D., Bravo M.1L., Iacono P., on Behalf of the MISTRAL. Study Group. Tiotropium reduces health resource utilization associated with COPD exacerbations [abstract 3204]. Eur. Respir. J. 2004; 24 (suppl. 48): 513s.

24. Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.

25. Brusasco V., Hodder R., Miravitlles M. et al. Health out-comes following six months' treatment with once-daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.

26. Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium and salmeterol. Chest 2002; 122: 47–55.

27. Синопальников А.И. Тиотропия бромид — новый антихолинергический препарат длительного действия. Рус. мед. журн. 2003; 22 (194): 1256–1261.

28. Фисенко В.П. Тиотропия бромид (Спирива) — новый М-холиноблокатор для лечения хронических обструктивных болезней легких. Пульмонология 2003; 4; 100–104.

29. Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–965.

30. Chodosh S., Flanders J. S., Kesten S. et al. Effective delivery of particles with the HandiHaler® dry powder inhalation system over a range of Chronic Obstructive Pulmonary Disease Severity. J. Aerosol Med. 2001; 14 (3): 309–315.

31. Dahl R., Backer V., Ollgaard B. et al. Assessment of patient performance of the HandiHaler® compared with the metered dose inhaler four weeks after instruction. Respir. Med. 2003; 97: 1126–1133.

32. van Noord J.A., de Munck D.R., Bantje T.A. et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J. 2000; 15: 878–885.

33. van Noord J.A., Aumann J., Janssens E. et al. Comparison of once-daily tiotropium, twice-daily formoterol and the free combination once-daily, in aitients with COPD. Am. J. Respir. Crit. Care Med. 2003; 167: A320.

34. Zuwallack R.L., Mahler D.A., Reilly D. et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661–1670.

35. Boy J., Dennis J.H., O'Driscoll B.R. et al. European Respiratory Society Guidelines on the use of nebulizers. Eur. Respir. J. 2001; 18 (1): 228–242.

36. Burge P.S., Calverley P.M., Jones P.W. et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297–1303.

37. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948–1953.

38. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902–1909.

39. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 1999; 353: 1819–1823.

40. Calverley P.M., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449–456.

41. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: (8): 1084–1091.

42. Lyseng1Williamson K.A., Keating G. Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease. Am. J. Respir. Med. 2002; 1 (4): 273–283.

43. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.

44. Лещенко И.В., Лившиц В. Р., Романовских А.Г. и др. Вопросы фармакоэкономики при лечении хронического обструктивного бронхита. Тер. арх. 2002; 3: 38–40.

45. Лещенко И.В. Значение бронхорасширяющей терапии при обострении хронической обструктивной болезни легких. Consilium Medicum 2004; 6 (10): 738–742.

46. Шмелев Е.И., Хмелькова Н.Г., Абубикиров А.Ф. Применение небулайзера при лечении беродуалом больных с обострением хронического обструктивного бронхита. Тер. арх. 2000; 3: 26–28.

47. Cochrane G.M. Compliance with nebulized therapy. Eur. Respir. Rev. 1997; 7 (51): 383–384.

48. Smaldone G.C. Current performance of nebulizers. Eur. Respir. Rev. 1997; 7 (51): 380–382.

49. Poole P.J., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2000; 2: CD001287.

50. Poole P., Black P. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br. Med. J. 2001; 322: 1271.

51. Nichol K.L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann. Intern. Med. 1999; 130: 397–403.

52. Nichol K.L., Mendelman P.M., Mallon K.P. et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. J.A.M.A. 1999; 282: 137–144.

53. Nichol K.L., Baken L., Wuorenma J., Nelson A. The health and economic benefits associated with pneumococcal vaccinations of elderly persons with chronic lung disease. Arch. Intern. Med. 1999; 159: 2437–2447.

54. Adams S.G., Anzueto A. Treatment of acute exacerbations of chronic bronchitis. Sem. Respir. Infect. 2000; 15: 234–247.

55. Fagon J.Y., Chastre J. Severe exacerbations of COPD patients; the role of pulmonary infections. Sem. Respir. Infect. 1996; 11: 109–118.

56. Miravitlles M., Guerrero T., Mayordomo C. et al. EOLO study group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistics regression analysis. Respiration 2000; 67: 495–501.

57. Adams S.G., Melo J., Luther M., Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345–1352.

58. Miravitles M., Murio C., Guerrero T., Gisbert R. for the DAFNE Study Group. Pharmacoeconimic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449–1455.

59. Aaron S.D., Vandermheen K.L., Clinch J.J. et al. Measurement of short-term changes in dyspnea and disease specific quality of life following an acute COPD exacerbation. Chest 2002; 121: 688–696.

60. Janson D.I. Anxiety and depression are related to the out-come of emergency treatment in patients with obstructive pulmonary disease. Chest 2002; 122: 1633–1637.

61. Grossman R., Mukherjee J., Vaughan D. et al. The Canadian Ciprofloxacin health economic study group. A 1-year community based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998; 113: 131–141.

62. Emerman C.L., Cydulk R.K. Effect of difficult albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive disease. Ann. Emerg. Med. 1997; 29: 474–478.

63. Turner M.O., Patel A., Ginsburg S. et al. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch. Intern. Med. 1997; 157: 1736–1744.

64. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 345: 456–460.

65. Thompson W.H., Nielson C.P., Carvalho P. et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am. J. Respir. Crit. Care Med. 1996; 154: 407–412.

66. Maltais F., Ostinelli J., Bourbeau J. et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2002; 1654: 698–703.

67. Anthonisen N.R., Manfreda J., Warren C.P.W. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.

68. Saint S.K., Bent S. Vittinghoff E. et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. J.A.M.A. 1995; 273: 957–960.

69. Swanson R.N., Lainez1Ventosilla A., De Salvo M.C. et al. Three-day azithromycin 500 mg q.i.d. vs 10-day clarithromycin 500 mg b.i.d. for acute exacerbation of chronic bronchitis in adults. Am. J. Respir. Crit. Care Med. 2002; I65: A269.

70. Anzueto A., Fisher C.L., Busman T. et al. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbations of chronic bronchitis. Clin.Ther. 2001; 23: 72–86.

71. Gotfried M.H, De Abate A, Fogarty C. et al. Comparison of 5-day, short course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin. Ther. 2001; 23: 97–107.

72. Wilson R., Kubin R., Ballin I. et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 1999; 44: 501–513.

73. Kessler R., Faller M., Fourgaut G. et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 158–164.

74. Garcia1Aymerich J., Monso E., Marrales R. et al. Risk factors for a chronic obstructive pulmonary disease exacerbation. Am. J. Respir. Crit. Care Med. 2001; 164: 1002–1007.

75. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Am. J. Respir. Crit. Care Med. 2001; 163: 283–291.

76. BTS Guideline. Non-invasive ventilation in acute respiratory failure. British Thoracic Standards of Care Committee. Thorax 2002; 57: 192–211.

77. Lightowler J.V., Wedzicha J.A., Elliot M., Ram S.F. Non invasive positive pressure ventilation to treat respiratory failure resulting from exacerbation of chronic obstructive pulmonary disease: Cochrane systematic review and metaanalysis. Br. Med. J 2003; 326: 185–189.


Рецензия

Для цитирования:


Лещенко И.В., Эсаулова Н.А. Основные положения международных клинических рекомендаций по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2005;(3):108-118. https://doi.org/10.18093/0869-0189-2005-0-3-108-118

For citation:


Leshchenko I.V., Esaulova N.A. Summary of international clinical recommendations on diagnosis and treatment of chronic obstructive lung disease. PULMONOLOGIYA. 2005;(3):108-118. (In Russ.) https://doi.org/10.18093/0869-0189-2005-0-3-108-118

Просмотров: 85


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)